Cargando…
Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
BACKGROUND: Positive cytology has been identified as an independent negative prognostic factor in patients with peritoneal metastases (PM) of colorectal origin. Liquid biopsy in plasma may detect increasing levels of circulating tumor DNA (ctDNA) and could help predict systemic relapse in patients w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758863/ https://www.ncbi.nlm.nih.gov/pubmed/33425029 http://dx.doi.org/10.1177/1758835920981351 |
_version_ | 1783627014950879232 |
---|---|
author | López-Rojo, Irene Olmedillas-López, Susana Villarejo Campos, Pedro Domínguez Prieto, Víctor Barambio Buendía, Javier Cortés Guiral, Delia García-Arranz, Mariano García-Olmo, Damián |
author_facet | López-Rojo, Irene Olmedillas-López, Susana Villarejo Campos, Pedro Domínguez Prieto, Víctor Barambio Buendía, Javier Cortés Guiral, Delia García-Arranz, Mariano García-Olmo, Damián |
author_sort | López-Rojo, Irene |
collection | PubMed |
description | BACKGROUND: Positive cytology has been identified as an independent negative prognostic factor in patients with peritoneal metastases (PM) of colorectal origin. Liquid biopsy in plasma may detect increasing levels of circulating tumor DNA (ctDNA) and could help predict systemic relapse in patients with colorectal cancer, but little is known about the role of liquid biopsy in peritoneal fluid. The aim of this study was to evaluate the prognostic value of peritoneal fluid and plasma liquid biopsy in patients undergoing complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CC-HIPEC). METHODS: A longitudinal prospective study was designed in patients with KRAS-mutated colorectal or appendiceal primary tumor, including PM of colorectal origin, pseudomyxoma peritonei and patients at high risk of developing PM (selected for second-look surgery). Eleven patients were recruited according to inclusion and exclusion criteria. ctDNA from plasma and peritoneal fluid before and after HIPEC was studied by droplet digital PCR looking for KRAS mutation. A close follow-up was scheduled (mean of 28.5 months) to monitor for systemic and peritoneal recurrences. RESULTS: All patients with positive plasma postHIPEC had systemic relapse and four patients died as a result, while those with negative plasma postHIPEC did not relapse. Patients with negative peritoneal ctDNA after CC-HIPEC did not present peritoneal relapse. Of six patients with positive peritoneal ctDNA postHIPEC, two presented peritoneal recurrence and four systemic relapses. CONCLUSIONS: Treatment with CC-HIPEC does not always neutralize ctDNA in peritoneal fluid, and its persistence after treatment may predict adverse outcome. Despite being a proof of concept, an adequate correlation between liquid biopsy in plasma and peritoneal fluid with both systemic and peritoneal relapse has been observed. |
format | Online Article Text |
id | pubmed-7758863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77588632021-01-08 Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy López-Rojo, Irene Olmedillas-López, Susana Villarejo Campos, Pedro Domínguez Prieto, Víctor Barambio Buendía, Javier Cortés Guiral, Delia García-Arranz, Mariano García-Olmo, Damián Ther Adv Med Oncol Original Article BACKGROUND: Positive cytology has been identified as an independent negative prognostic factor in patients with peritoneal metastases (PM) of colorectal origin. Liquid biopsy in plasma may detect increasing levels of circulating tumor DNA (ctDNA) and could help predict systemic relapse in patients with colorectal cancer, but little is known about the role of liquid biopsy in peritoneal fluid. The aim of this study was to evaluate the prognostic value of peritoneal fluid and plasma liquid biopsy in patients undergoing complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CC-HIPEC). METHODS: A longitudinal prospective study was designed in patients with KRAS-mutated colorectal or appendiceal primary tumor, including PM of colorectal origin, pseudomyxoma peritonei and patients at high risk of developing PM (selected for second-look surgery). Eleven patients were recruited according to inclusion and exclusion criteria. ctDNA from plasma and peritoneal fluid before and after HIPEC was studied by droplet digital PCR looking for KRAS mutation. A close follow-up was scheduled (mean of 28.5 months) to monitor for systemic and peritoneal recurrences. RESULTS: All patients with positive plasma postHIPEC had systemic relapse and four patients died as a result, while those with negative plasma postHIPEC did not relapse. Patients with negative peritoneal ctDNA after CC-HIPEC did not present peritoneal relapse. Of six patients with positive peritoneal ctDNA postHIPEC, two presented peritoneal recurrence and four systemic relapses. CONCLUSIONS: Treatment with CC-HIPEC does not always neutralize ctDNA in peritoneal fluid, and its persistence after treatment may predict adverse outcome. Despite being a proof of concept, an adequate correlation between liquid biopsy in plasma and peritoneal fluid with both systemic and peritoneal relapse has been observed. SAGE Publications 2020-12-18 /pmc/articles/PMC7758863/ /pubmed/33425029 http://dx.doi.org/10.1177/1758835920981351 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article López-Rojo, Irene Olmedillas-López, Susana Villarejo Campos, Pedro Domínguez Prieto, Víctor Barambio Buendía, Javier Cortés Guiral, Delia García-Arranz, Mariano García-Olmo, Damián Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title | Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title_full | Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title_fullStr | Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title_full_unstemmed | Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title_short | Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
title_sort | liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758863/ https://www.ncbi.nlm.nih.gov/pubmed/33425029 http://dx.doi.org/10.1177/1758835920981351 |
work_keys_str_mv | AT lopezrojoirene liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT olmedillaslopezsusana liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT villarejocampospedro liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT dominguezprietovictor liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT barambiobuendiajavier liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT cortesguiraldelia liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT garciaarranzmariano liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy AT garciaolmodamian liquidbiopsyinperitonealfluidandplasmaasaprognosticfactorinadvancedcolorectalandappendicealtumorsaftercompletecytoreductionandhyperthermicintraperitonealchemotherapy |